Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 2/20 | 0.42 |
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.42 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.42 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.42 |
| ▸ | PRKX | P51817 | 2/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.42 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL540001 | 1.00 | GPR142 (0.49) | GPR142ALDH1A1AAK1PPIDF10 | |
| Hydrochloric Acid SCHEMBL1151207 | 1.00 | GPR142 (0.49) | GPR142ALDH1A1AAK1PPIDF10 | |
| SCHEMBL540000 | 0.98 | GPR142 (0.50) | GPR142ALDH1A1AAK1PPIDF10 | |
| SCHEMBL540302 | 0.98 | GPR142 (0.50) | GPR142ALDH1A1AAK1PPIDF10 | |
| Hydrochloric Acid SCHEMBL5494193 | 0.91 | ALDH1A1 (0.49) | GPR142ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL2106188 | 0.91 | ALDH1A1 (0.49) | GPR142ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL27528013 | 0.91 | ALDH1A1 (0.49) | GPR142ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL5494194 | 0.91 | ALDH1A1 (0.49) | GPR142ALDH1A1PTGS2 | |
| SCHEMBL19699287 | 0.89 | ALDH1A1 (0.47) | GPR142ALDH1A1PTGS2 | |
| SCHEMBL2059222 | 0.89 | ALDH1A1 (0.47) | GPR142ALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | VTV THERAPEUTICS LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| CN-102378574-B | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA INC | 2013-11-20 | — | — | CN | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| CN-102378574-A | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA INC | 2012-03-14 | — | — | CN | disclosed |
| EP-2413693-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | ROCK2 1282/4885ROCK1 1190/4885PTGS2 553/4885 |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLP1R, GIPR, GPR119 | ROCK2 1282/4885ROCK1 1190/4885PTGS2 553/4885 |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | GLP1R, GIPR, GPR119 | ROCK2 2668/4885ROCK1 1121/4885PTGS2 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.